P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 Review of First Quarter F’15 Results Matt Mannelly, CEO & President Ron Lombardi, CFO August 7, 2014 Exhibit 99.2

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s growth strategies, competitive position, product development and acquisitions, business trends, creation of shareholder value, ability to integrate the Insight and Hydralyte acquisitions, the timing of closing and the impact of the Insight acquisition, the growth and market position of the Company’s brands, and the Company’s future financial performance. Words such as “continue,” “will,” “expect,” “anticipate,” “likely,” “estimate,” “may,” “should,” “could,” “would,” and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, failure to satisfy the closing conditions for the Insight acquisition, the failure to successfully integrate the Insight or Hydralyte businesses or future acquisitions, the failure to successfully commercialize new and enhanced products, the severity of the cough/cold season, general economic and business conditions, competitive pressures, the effectiveness of the Company’s brand building investments, fluctuating foreign exchange rates, and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2014. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise. Safe Harbor Disclosure

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 3 Agenda for Today’s Discussion I. First Quarter FY2015: Performance Highlights II. First Quarter FY2015: Financial Overview III. Updated Perspective on the M&A Market IV. FY2015 Outlook and the Road Ahead

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 4 I. First Quarter FY2015: Performance Highlights

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 5 Solid Start to the Fiscal Year  Q1 consolidated net revenue of $145.7 million, up 2.2% versus the prior year  Adjusted E.P.S. of $0.41(1), up 2.5% versus the prior year corresponding quarter  Strong Free Cash Flow of $29.2(1) million, up 36.1% versus the prior year corresponding quarter  Core OTC consumption growth of 2.5% (excluding products impacted by pediatric and GI category dynamics)  Continued investment in brand building efforts − New product introductions of Fresh Guard and Beano Dairy Defense − New advertising campaigns for Fresh Guard, Beano and Clear Eyes with spokesperson Vanessa Williams − “Speedy” brand exposure through sports marketing association with Daytona / Pocono champion Dale Earnhardt Jr.  Closed acquisition of Hydralyte on April 30th. Integration well underway  Pending acquisition of Insight Pharmaceuticals on track to close by September 30th  On track to continue to deliver strong financial performance in FY2015 − Full year sales growth +15% – 18% − Adjusted E.P.S $1.75 – $1.85(1) − Free Cash Flow of approximately $150 million(1) Notes: (1) These Non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the “About Non-GAAP Financial Measures” section.

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 6 Transitional Market 6.9% 10.5% 6.9% 6.4% 0.8% (4.2%) (8.1%) (8.2%) (1.8%) Q1 Q2 Q3 Q4 Q1 3.6% 0.2% (1.7%) (0.7%) 2.5% Core OTC Consumption Growth Source: Latest 12-week IRI multi-outlet retail dollar sales growth for relevant quarter. Note: Data reflects retail dollar sales percentage growth versus prior period. (1) Excludes PediaCare, Little Remedies and Beano. Excluding Cough/Cold Competitive Returns / GI Category Dynamics(1) FY’13 FY’14 Q2 Q3 Improved Consumption Performance in Q1… FY’15 Q4 Q1

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 7 …And Three Consecutive Quarters of Consumption Growth Outpacing Shipments… Source: Latest 12-week IRI multi-outlet retail dollar sales growth for relevant quarter. Note: Data reflects retail dollar sales percentage growth versus prior period. (1) Excludes PediaCare, Little Remedies and Beano. Core OTC Consumption vs. Revenue Growth(1) 3.6% 0.2% (1.7%) (0.7%) 2.5%3.5% 5.7% (8.5%) (4.1%) (3.7%) Core OTC Consumption Growth Core OTC Net Revenue Growth FY’14 FY’15 Q1 Q2 Q3 Q4 Q1 0.1% (5.5%) 6.8% 3.4% 6.2% G rowt h Dif fe ren ce

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 8 Core OTC Market Share(1) Source: IRI multi-outlet retail dollar sales growth for relevant quarter. Note: Data reflects retail dollar sales market share. (1) Excludes PediaCare, Little Remedies and Beano. …Leading to Record Market Share Gains 8.8% 9.7% 10.2% 10.2% 10.1% 10.2% 10.6% FY'10 FY'11 FY'12 FY'13 FY'14 L52 L12

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 9 Luden’s: Driving Growth on a 130 Year Old Brand 2010 2013 Source: IRI MULO + C-Store, 52 weeks ending 31-Dec-2013. Note: Data reflects retail dollar sales.  Strong equity rooted in great tasting, soothing relief  Minimal investment in recent years  Consumption growth had flattened to +0.5%  Consumption: +26% Growth — 3-year CAGR +8%, nearly twice the rate of the category — Luden’s Wild Cherry 30CT: #1 selling Throat Drop 2010 2011 2012 2013 +8% CAGR

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 0 Luden’s Brand Building: Model in Action Investment in Brand Building Product Innovation  Print and digital advertising to re-ignite awareness  Packaging transformation to modernize the brand  Merchandising enhanced in-store presence  New flavors for a new generation and broader consumer appeal — New! Watermelon and Blue Raspberry flavors — New! Sugar Free Black Cherry flavor

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 1 FY12 FY13 FY14 FYTD15 Investment Focus “Basics” Social media and sponsorships Mobile activation Leveraging “Big Data” % of A&P <5% ~5% ~10% ~15% PBH Revenue Growth Digital and Social Media: An Investment for the Future

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 2 Brand Activation Results  Targeted travel-oriented shoppers and websites with online advertising  Drove consumption +9.2% in L-12  Crowdsourcing consumer feedback of new product ideas  Launched 3 new flavors  Identified brand influencers via social listening to engage in 1x1 dialogue  Increased social engagement metrics 3x Digital Engagement Drives Brand Relevance and Sales

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 3 Location-Based, Real-Time Mobile Marketing is the Future

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 4 Hydralyte Integration Proceeding on Schedule  Integration of Hydralyte into Care Pharma underway − Transition to Care Pharma direct sales force September 1st  Innovation and new product development are underway − 3 new products just introduced: Hydralyte Colour Free, and Orange & Lemon-Lime Sports Tubs  Optimizing marketing plan − New ad campaign supported by TV, sampling, instore promotional activities, and PR  Geographic expansion into New Zealand scheduled for early fall  Evaluating supply chain improvement opportunities Early Initiatives Underway New Product Development  New product launch marketing − In-store promotions planned to support Colour Free − HCP sampling − PR campaign to support the Sports Tubs − Online advertising with sporting groups

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 5 Net Sales Pro Forma Adjusted EBITDA(1) Sc al e P rofi ta b ili ty Pro Forma Adjusted Gross Margin (% Net Sales) Pro Forma Adjusted EBITDA Margin (% Net Sales) $602 ~$800 FY2014 Pro Forma 57% ~60% FY2014 Pro Forma 34% ~37% FY2014 Pro Forma +33% $204 ~$300 FY2014 Pro Forma +47% +300 bps +300 bps Notes: (1) Pro Forma Adjusted EBITDA is a Non-GAAP financial measure and is arrived at by taking Pro Forma Net Income of $89 million and adding back depreciation and amortization of $31 million, interest expense of $103 million, income taxes of $52 million and transition, integration and purchase accounting items of $25 million to arrive at $300 million (2) Pro Forma Adjusted Gross Margin excludes $5 million of charges related to purchase accounting inventory step-up (3) Pro Forma Adjusted EBITDA margin excludes depreciation and amortization of $31 million, interest expense of $103 million, income taxes of $52 million and transition, integration and purchase accounting items of $25 million (1) (2) (3) Transformational Acquisition of Insight Pharmaceuticals On Track to Close by September 30th

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 6 II. First Quarter FY2015: Financial Overview

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 7 Selected Observations on First Quarter Performance  Solid overall financial performance in the quarter consistent with expectations − Net Revenue growth of 2.2% based on increasingly diversified portfolio − Adjusted Gross Margin of 56.3%(1) reflects current retail and competitive environment − Expect Gross Margins of approximately ~60% post acquisition of Insight Pharmaceuticals − Consistent free cash flow of $29.2(1) million, up 36.1% versus the prior year corresponding quarter  On track to achieve full year outlook $142.5 $53.3 $21.4 $145.7 $51.0 $29.2 Net Revenue Adjusted EBITDA Adjusted EPS Free Cash Flow Q1 FY’15Q1 FY’14 2.2% (4.2%) 2.5% 36.1% $0.40 $0.41 (1) (1) (1,2) Dollar values in millions, except per share data Notes: (1) These non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the “About Non-GAAP Financial Measures” section. (2) Free cash flow is a non-GAAP financial measure and is also reconciled to reported net income on page 20.

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 8 Selected Observations on First Quarter Performance (Cont’d)  Company announced today its plan to launch financing for the acquisition of Insight Pharmaceuticals − Continue to expect to close transaction by September 30th − Single, minor brand divestiture expected to be required from the FTC and expected to be completed concurrent with closing − Transaction expected to be funded under Term Loan accordion. Pro forma leverage of 5.7x − Rapid deleveraging expected due to unique high free cash flow generation model − Capital structure allows for flexibility to pursue additional acquisition opportunities

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 1 9 Q1 FY'15 Q1 FY'14 % Chg Net Revenue 145.7$ 142.5$ 2.2% Adj. Gross Margin(1) 82.0 83.0 (1.2%) % Margin 56.3% 58.3% A&P 19.1 18.7 2.2% % Net Revenue 13.1% 13.1% Adj. G&A(1) 11.9 11.1 7.3% % Net Revenue 8.1% 7.8% Adjusted EBITDA(1) 51.0$ 53.3$ (4.2%) % Margin 35.0% 37.4% D&A 3.0 3.3 (9.4%) % Net Revenue 2.0% 2.3% Adj. Operating Income(1) 48.1 50.0 (3.9%) % Net Revenue 33.0% 35.1% Adjusted Net Income(1) 21.5$ 21.1$ 2.1% Adjusted Earnings Per Share(1) 0.41$ 0.40$ 2.5% Earnings Per Share - As Reported 0.32$ 0.40$ (20.0%) Net Income - As Reported 16.7$ 20.7$ (19.1%)  Net Revenue increased $3.2 million, or 2.2% due to Core OTC shipment trends improving over 2H FY2014 in addition to the Care and Hydralyte acquisition  Adjusted Gross Margins reflects current retail and competitive environment  Continued strong A&P support behind brand building  Adjusted G&A as a percent of Net Revenue up slightly due to acquisitions  Adjusted Net Income and Adjusted EPS increase ~2.5%  Reported Net Income and EPS include costs associated with the Hydralyte and Insight transactions First Quarter Consolidated Financial Summary Dollar values in millions, except per share data Notes: (1) These Non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the “About Non-GAAP Financial Measures” section. Q1 FY’15 Comments

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 0 Debt Profile & Financial Compliance:  Total Net Debt at 6/30/14 of $957 million comprised of: – Cash on hand of $16 million – $323 million of term loan and revolver – $650 million of bonds  Leverage ratio(2) of ~4.6x Strong Free Cash Flow Generation Dollar values in millions Note: (1) Operating cash flow is a Non-GAAP financial term and is equal to GAAP net cash provided by operating activities. (2) Leverage ratio reflects net debt / covenant defined EBITDA. (3) Free Cash Flow is a Non-GAAP financial measure and is reconciled to GAAP net cash provided by operating activities in our earnings release in the “About Non-GAAP Financial Measure” section. Cash Flow Comments Q1 FY'15 Q1 FY'14 Net Income - As Reported 16.7$ 20.7$ Depreciation & Amortization 3.0 3.3 Other Non-Cash Operating Items 10.0 9.2 Working Capital (0.0) (10.4) Operating Cash Flow(1) 29.7$ 22.8$ Additions to Property a Equipment (0.5) (1.4) Free Cash Flow(3) 29.2$ 21.4$ Full year cash flow of ~$150 million, in line with expectations

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 1 III. Updated Perspective on the M&A Market

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 2 Potentially Significant Pool of M&A Opportunities Resulting from Large OTC M&A Deals and Announced Wholesale Divestitures  Divest or exit 90 to 100 smaller brands  Mostly sales of under $100 million  Focus on 70 to 80 remaining brands  Combined portfolio with potential for rationalization  Prior success in executing broad divestiture  M&A history with Prestige Brands  Combined portfolio with potential for rationalization  Primarily North American focus Brand Rationalization

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 3 Dollar values in millions Source: Euromonitor (2013) 0% 20% 40% 60% 80% 100% Retail Sales: % of Retail Sales: 29% 16% 15% 11% 8% 7% 6% 8% Oral Health CCAS $4,490 Analgesics $1,754 $1,325 VMS / Nutrition Skin Care GI Smoking Cessation Misc. Other $2,490 $2,331 $1,190 $1,101 $945 Other Other Other Other Other Other Other ACC Existing Category Presence Illustrative Example: Combined Portfolio ~$4 Billion in Retail Sales of Brands Less Than $100 MM Notes: (1) Source: EuroMonitor

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 4 M&A Market as Prolific as it has been in the Last Five Years  Likely portfolio rationalizations from existing transactions in the next 12 – 24 months  GSK prior “bottom 10%” divestiture plan as well as P&G announcement may set the stage for similar announcements from other large players  Additional opportunities from family-owned businesses and private equity owners Ready and Able to Capitalize on New Market Opportunities Aggressive and Disciplined Well Established M&A Criteria Successful Value Creation Strategy Continued M&A Growth Ambitions

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 5 IV. FY2015 Outlook and the Road Ahead

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 6 Business and Environment Positions Prestige Brands to Continue to Create Shareholder Value − Improved Prestige Brands consumption trends leading to market share gains − Challenging retail environment provides some uncertainty − Positive momentum into Q2, however strong year-over-year comps and uncertain cough/cold order patterns and levels − Prior revenue outlook flat to -3% for 1H FY2015 − Continued new product introductions and investment in brand building communication vehicles for FY2015 − Invest and innovate in Core OTC brands − Continue to build new product engine − Remain aggressive and disciplined − Effectively integrate and acquisitions − Capitalize on OTC consolidation and major company’s announcements − Full year revenue growth +15% – 18% − Adjusted E.P.S $1.75 – $1.85(1) − Free Cash Flow of approximately $150 million(1) Cautiously Optimistic Brand Building in Focus Prolific M&A Outlook Confident in Full FY2015 Year Outlook Notes: (1) These Non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the “About Non-GAAP Financial Measures” section.

P R E S T I G E B R A N D S F i r s t Q u a r t e r F ’ 1 5 R e s u l t s 2 7